.jpg?#)
Transcend's neuroplastogen notches Phase 2 win to treat PTSD
Transcend Therapeutics’ PTSD treatment succeeded in a mid-stage study, propelling the scrappy company of less than 20 people toward a Phase 3 trial that could begin at the start of next year. The placebo-controlled results ...
Transcend Therapeutics’ PTSD treatment succeeded in a mid-stage study, propelling the scrappy company of less than 20 people toward a Phase 3 trial that could begin at the start of next year.
The placebo-controlled results ...
